Urinary incontinence oxybutynin

Anderson, R.U., et al. 1999. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol 161 1809. 

Versi, E., et al. 2000. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstet Gynecol 95 718. 

Oxybutynin Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency... 

Tertiary a-hydroxy acids are key components of a number of muscarinic receptor antagonists, such as oxybutynin (Ditropan as a racemic mixture), which is prescribed for the treatment of urinary incontinence and exhibits classical antimuscarinic side effects, such as dry mouth.88 Because biological results suggested that (.SVoxybutynin displayed an improved therapeutic profile compared to its racemic counterpart, a general and practical entry to optically pure key subunit (S)-90 became of primary importance.89 In their investigations, researchers at Sepracor considered the advantage... 

Oxytrol Oxybutynin Urinary incontinence Watson Pharma... 

Oxytrol is a three- or four-day patch used for the treatment of urinary incontinence that was recently approved by the FDA. It delivers the active ingredient oxybutynin. Oxybutynin is an antispasmotic and anticholinergic agent with a molecular weight of 357. Oxybutynin is considered to be a lipophilic drug. Oxytrol is a matrix-type patch with a surface area of 39 cm2 and contains 36 mg of oxybutynin. Oxytrol has an in vivo delivery rate of approximately 3.9mg/day. 

Trade names Albert (Oxybutynin) Cystrin Ditropan (Ortho-McNeil) Dridase Novitropan Oxyban Tropax Indications Neurogenic bladder, urinary incontinence Category Anticholinergic Muscarinic antagonist Half-life 1-2.3 hours... 

Ouslander JG, Schnelle JF, Uman G, et al. Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents A placebo-controlled trial. J Am Geriatr Soc 1995 43 610-617. 

Schmidt RA, The Oxybutynin XL Study Group. Efficacy of controlled-release, once-a-day oxybutynin chloride for urge urinary incontinence. Jerusalem, International Continence Society, Sept. 14—17, 1998 188. 

Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003 62 237-242. 

Susset JG, Gleason DM, White CF, et al. Open-label safety and dose conversion/determination of once-daily OROS oxybutynin chloride for mge urinary incontinence. J Urol 1998 159(Suppl) 36. 

Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001 166 140-145. 

Oxybutynin chloride is an anticholinergic that increases bladder capacity, diminishes frequency of uninhibited contractions of detrusor muscle and delays initial desire to void. It is indicated in the treatment of symptoms of bladder instability associated with voiding in patients with uninhibited and reflex neurogenic bladder (e.g., urinary leakage, dysuria) and treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. 

Trospium is a quaternary amine long used in Europe and approved recently for use in the United States for treatment of overactive bladder. It has been shown to be as effective as oxybutynin with better tolerability. Solifenacin is newly approved for overactive bladder with a favorable efficacy side effect ratio. Stress urinary incontinence has been treated with some success with duloxetine (Yentreve), which acts centrally to influence serotonin and norepinephrine levels. 

Overactive urinary bkuMer disease can be successfully treated with muscarinic antagonists, primarily tolterodine and trospium chloride, which lower intravesicular pressure, increase capacity, and reduce the frequency of contractions by antagonizing parasympathetic control of the bladder. Oxybu-tynin is used as a transdermal system (oxytrol) that delivers 3.9 mg/day and is associated with a lower incidence of side effects than the oral immediate- or extended-release formulations. Tolterodine is metabolized by CYP2D6 to a 5-hydroxymethyl metabolite since this metabolite possesses similar activity to the parent drug, variations in CYP2D6 levels do not affect the duration of drug action. Trospium is as effective as oxybutynin, with better tolerability. Solifenacin is newly approved for overactive bladder with a favorable efficacy side effect ratio. Stress urinary incontinence has been treated with some success with duloxetine (YENTREVE), which acts centrally to influence 5-HT and NE levels. 

Tolterodine, a competitive muscarinic receptor antagonist, is considered first-line therapy in patients with urinary frequency, urgency, or urge incontinence. Controlled studies demonstrate that tolterodine is more effective than placebo and as effective as oxybutynin IR in decreasing the number of daily micturitions and increasing the volume voided per micturition. However, most studies have not shown a decrease in the number of daily UI episodes as compared with placebo. 

Urinary frequency, urgency and incontinence flavoxate, tolterodine, oxybutynin (antimuscarinics) may be useful they may cause retention of urine if there is anatomical obstruction. The pain (with reflex muscle spasm) of an indwelling catheter may be alleviated by diazepam. 

Amarenco G, Marquis P, McCarthy C, Richard E. Efficacy of oxybutynin on health related quality of life (HRQL) in 1701 women suffering from urinary urge incontinence (UUl). Eur Urol 1998 33(Suppl l) 32-38. 

Gleason DM, Susset J, White C. Evalrration of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Urology 1999 54 420-423. 

---